Therefore, strategies aimed to reduce plasma phosphate like the use of phosphate binders or reducing intake should be better adjusted or given in combination with insulin sensitizing drugs particularly to those CKD subjects at greater risk of developing sarcopenia. This evidence concerns the gene INS and sarcopenia.